Jenburkt Pharma last traded at ₹915.05 (2026-10-13). Over the past month the stock moved -11.9%, three months the stock moved -21.0%, year the stock moved -17.3%. Its closing range over 52 weeks is ₹892.10 – ₹1,272.90, with the latest close 28.1% below the high.
Closing prices up to 2026-10-13.
Incorporated in 1985, Jenburkt Pharmaceuticals Ltd manufactures and markets branded Pharmaceuticals and health care products[1]
Business Overview:[1] JPL manufactures and markets pharmaceutical formulations in India and internationally across 13 countries. It promotes 85 brands across 1 Lac+ doctors regularly. Company has 1,000+ stockists and its reach extends to 4 Lac+ pharmacies across the globe. JPL caters to large government, semi-government institutions, missionary hospitals, public sector enterprises, etc.
In the latest quarter (Jun 2026), Jenburkt Pharma reported sales of ₹35.51 crore (-0.1%) and net profit of ₹5.89 crore (-24.4%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 35.51 | 6.03 | 16.98 | 5.89 | 13.35 |
| Mar 2026 | 44.63 | 14.25 | 31.93 | 10.85 | 24.58 |
| Dec 2025 | 43.02 | 7.43 | 17.27 | 5.93 | 13.44 |
| Sep 2025 | 45.56 | 13.11 | 28.78 | 10.16 | 23.02 |
| Jun 2025 | 35.53 | 8.95 | 25.19 | 7.79 | 17.65 |
| Mar 2025 | 41.05 | 10.86 | 26.46 | 8.54 | 19.35 |
| Dec 2024 | 36.89 | 8.82 | 23.91 | 6.51 | 14.75 |
| Sep 2024 | 41.22 | 11.43 | 27.73 | 9.60 | 21.75 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +7.7% | +3.4% | +5.7% | +9.2% | +10.5% | +16.6% | +8.7% | -0.1% |
| Operating profit growth | +25.6% | +22.7% | +10.3% | -3.6% | +14.7% | -15.8% | +31.2% | -32.6% |
| Net profit growth | +31.1% | +20.6% | +8.4% | +5.0% | +5.8% | -8.9% | +27.0% | -24.4% |
| EPS growth | +31.1% | +20.5% | +8.3% | +5.0% | +5.8% | -8.9% | +27.0% | -24.4% |
| OPM % | 27.7% | 23.9% | 26.5% | 25.2% | 28.8% | 17.3% | 31.9% | 17.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
In the latest year (Mar 2026), Jenburkt Pharma reported sales of ₹169.00 crore (+11.2%) and net profit of ₹35.00 crore (+9.4%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 169.00 | 44.00 | 26.00 | 35.00 | 78.72 |
| Mar 2025 | 152.00 | 40.00 | 27.00 | 32.00 | 72.64 |
| Mar 2024 | 142.00 | 33.00 | 23.00 | 26.00 | 58.87 |
| Mar 2023 | 137.00 | 30.00 | 22.00 | 25.00 | 55.76 |
| Mar 2022 | 124.00 | 27.00 | 22.00 | 22.00 | 48.59 |
| Mar 2021 | 109.00 | 20.00 | 18.00 | 16.00 | 35.95 |
| Mar 2020 | 119.00 | 20.00 | 17.00 | 15.00 | 32.40 |
| Mar 2019 | 123.00 | 25.00 | 20.00 | 20.00 | 43.14 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +7.0% | -3.3% | -8.4% | +13.8% | +10.5% | +3.6% | +7.0% | +11.2% |
| Operating profit growth | +4.2% | -20.0% | +0.0% | +35.0% | +11.1% | +10.0% | +21.2% | +10.0% |
| Net profit growth | +17.6% | -25.0% | +6.7% | +37.5% | +13.6% | +4.0% | +23.1% | +9.4% |
| EPS growth | +15.0% | -24.9% | +11.0% | +35.2% | +14.8% | +5.6% | +23.4% | +8.4% |
| OPM % | 20.0% | 17.0% | 18.0% | 22.0% | 22.0% | 23.0% | 27.0% | 26.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
No AI analysis generated yet for Jenburkt Pharma.
Get Free AI Stock Analysis FREE →Counter Cyclical raises Jenburkt Pharma stake to 5.01% via open market - scanx.trade
Counter Cyclical raises Jenburkt Pharma stake to 5.01% via open market - scanx.trade
Jenburkt Pharma - Quaterly Results
Jenburkt Pharma shares were last quoted at ₹915.05 (-3.2% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
Jenburkt Pharma has a price-to-earnings (P/E) ratio of 12.85 and a price-to-book (P/B) ratio of 2.08. The industry P/E is 53.45.
The 52-week high of Jenburkt Pharma is ₹1,321.00 and the 52-week low is ₹944.00.
The market capitalisation of Jenburkt Pharma is about ₹421.96 crore.
In the latest quarter (Jun 2026), Jenburkt Pharma reported sales of ₹35.51 crore (-0.1%) and net profit of ₹5.89 crore (-24.4%), compared with the same quarter last year.
This page is for information and is not investment advice. As per the data shown here, Jenburkt Pharma has a 3-year ROE of 20.00%, 3-year profit growth of 15.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
Promoters hold about 46.62% of Jenburkt Pharma.
Jenburkt Pharma belongs to the Pharmaceuticals & Drugs sector.